l General Information |
Product Name | Lesinurad |
General description | Lesinurad is a selective uric acid reabsorption inhibitor (SURI) under investigation for treatment of gout in combination with xanthine oxidase inhibitors. |
Synonym | RDEA 594; 2-[[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-1,2,4-triazol-3-yl]sulfanyl]acetic acid |
Purity | ≥99.0%(HPLC) | CAS Number | 878672-00-5 |
Formula | C17H14BrN3O2S | Molecular Weight | 404.28 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | White to beige Solid |
Solubility(25°C) | DMSO | ≥45mg/ml |
Ethanol | ≥35mg/ml |
Water | Very slightly soluble |
l Biological Information |
Biochem/Physiol
Actions | Lesinurad is a selective inhibitor of uric acid reabsorption which is used in combination with other agents in the therapy of gout. Lesinurad has had limited clinical use, but has not been associated with serum enzyme elevations during therapy or with instances of clinically apparent liver injury. |
l Storage |
Storage temp. | -20°C |
l Precautions and Disclaimer |
This product is for R&D use only, not for drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
